Impact of HIV infection, highly active antiretroviral therapy, and hepatitis C coinfection on serum interleukin-27.
A newly described cytokine, interleukin-27 (IL-27), that activates naive CD4 T cells, has recently been shown to be an anti-HIV cytokine. However, the effect of HIV infection on IL-27 expression has not been characterized. We found that clinical characteristics, including HIV viral load, hepatitis C virus coinfection, and CD4 T cell counts, were associated with changes in serum IL-27. Overall, our results suggest circulating HIV may suppress IL-27, a critical concept in treatment development with this cytokine.
Guzzo
Christina
C
Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada.
Hopman
Wilma M
WM
Che Mat
Nor Fazila
NF
Wobeser
Wendy
W
Gee
Katrina
K
D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy; D015497:HIV-1; D006526:Hepatitis C / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D020381:Interleukin-17 / Q000097:blood*; D019562:Viral Load
D020381:Interleukin-17